The Apex Times
Above the Noise
Business Wire
BusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex Times
Back to front
Jim Cramer points to drug stocks, mentions Johnson & Johnson as he argues tech leadership has faded
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 12, 10:54 AM EDT

Jim Cramer points to drug stocks, mentions Johnson & Johnson as he argues tech leadership has faded

In a market commentary carried by Yahoo Finance, Jim Cramer said he prefers drug-related stocks over parts of the tech complex and cited Johnson & Johnson as an example while discussing his current stance toward the drug sector.

By The Apex Times Newsroom3 min readAI-assisted Apex article

Jim Cramer used a segment of his market commentary to argue that investors can no longer rely on technology stocks to lead the market, saying the leadership trade he has been watching does not look trustworthy anymore. In that context, he turned to healthcare, highlighting drug stocks as a category he is more comfortable with.

Johnson & Johnson, traded on the New York Stock Exchange under the ticker JNJ, was among the companies Cramer mentioned during the discussion. The Yahoo Finance report framed his comments as part of a broader preference for drug stocks at the moment rather than a bet on tech, even as market leadership remains contested.

The exchange also reflected a familiar theme in financial television commentary: rotation out of one perceived leadership group into another. Here, the rotation was toward pharmaceuticals, with drug-related names positioned as offering a steadier foundation than the tech complex, at least according to Cramer’s stated sentiment in the segment.

Still, the Yahoo Finance write-up did not lay out specific fundamentals or new company developments for Johnson & Johnson. It did not describe any particular product timeline, trial result, regulatory decision, or financial guidance tied to JNJ in the post or link that carried the commentary. As a result, readers are left with a view of positioning and sentiment, not fresh operational information from the company.

For investors tracking drug stocks, the relevance of the comment is less about immediate, verifiable catalysts and more about the mood of the market. Sentiment shifts like this can influence near-term trading activity, especially in large-cap healthcare names that are widely held and frequently used as “core” exposures in portfolios.

Johnson & Johnson’s size and diversification make it a frequent reference point in healthcare discussions. The company is widely known for spanning both prescription medicines and other healthcare businesses, which can help explain why it shows up when commentators talk about “drug stocks” as a category. But the Yahoo Finance report did not provide a breakdown of how those segments are contributing to Cramer’s view.

What is not clear from the Yahoo Finance article is whether Cramer’s positive tone toward drug stocks was driven by any specific data point, sectorwide valuation argument, or a view on near-term earnings. The post, as represented in the headline and description, reads as a sentiment call rather than an evidence-backed thesis that can be independently verified through cited company documents in the material provided.

Investors watching the space next may look for confirmation from company-level disclosures and sector reports that align with the sentiment Cramer expressed, such as updates on demand trends, pipeline progress, or regulatory milestones across major pharmaceutical companies. Absent those disclosures in the cited material, the immediate takeaway remains that a high-profile market commentator is leaning toward drugs rather than tech, with JNJ named as one example.

Why It Matters

  • A shift in a prominent commentator’s positioning can affect short-term investor attention toward healthcare and pharmaceutical names.
  • By contrasting drug stocks with technology leadership, the commentary highlights an ongoing debate about what should drive broad market performance.
  • Large, widely followed names like Johnson & Johnson can become focal points when investors rotate across sectors.
  • Because the cited material does not include new company fundamentals, the near-term impact is likely more about sentiment and flows than confirmed business progress.

Sources

Key Facts

  • Jim Cramer said he prefers drug stocks and discussed that view in a market commentary carried by Yahoo Finance.
  • The Yahoo Finance report states Cramer argued that technology stocks can no longer be trusted to lead the market.
  • Johnson & Johnson was among the companies mentioned by Cramer during the segment.
  • Johnson & Johnson trades on the NYSE under the ticker JNJ.
  • The Yahoo Finance post presented the remarks as sentiment around the drug sector, without detailing a specific Johnson & Johnson catalyst in the provided description.

Healthcare Related